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Protocol-Based Care for Early Septic Shock
To the Editor: In the Protocolized Care for Early Septic Shock (ProCESS) study (May 1 issue),1
the investigators report that protocol-based early
goal-directed therapy (EGDT) did not improve
the outcome in patients with septic shock. Since
fluid therapy is an essential component of EGDT,
it would be useful to know what types of fluid
were administered. During the first 72 hours of
care, patients received about 6.5 liters of intravenous fluids, and there was a mean increase in the
serum chloride level from 100 mmol per liter to
between 106 and 108 mmol per liter. In a recent
study,2 a similar increase in the serum chloride
level from 103 to 108.5 mmol per liter 60 minutes
after the infusion of 2 liters of 0.9% sodium chloride in healthy participants was associated with a
40% decrease in renal blood-flow velocity (as
measured in centimeters per second) and the
perfusion of renal cortical tissue. Additional evidence supports the adverse renal effects of hyperchloremia.2-5 Since such adverse effects might
have modified the findings, and since the administration of large amounts of hyperchloremic
0.9% sodium chloride is the probable cause of
the reported hyperchloremia, can the authors
provide information on the types of fluid that
were administered?
Hans-Joachim Priebe, M.D.
University of Freiburg
Freiburg, Germany

hans-joachim.priebe@uniklinik-freiburg.de
No potential conflict of interest relevant to this letter was reported.
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DOI: 10.1056/NEJMc1406745

To the Editor: In the ProCESS study, all three
study groups had an improvement in the rate of
death (ranging from 17 to 19 percentage points),
as compared with values predicted by their score
on the Acute Physiology and Chronic Health
Evaluation (APACHE) II, which shows that protocolized care does work. As compared with the
patients in the Early Goal-Directed Therapy
study,1 the patients in the ProCESS study had a
lower severity of illness because the initial lactate
values were lower and the inclusion criteria included a 1-liter fluid bolus instead of 20 to 30 ml
per kilogram of body weight.2 The majority of
the study sites had preexisting sepsis programs
that were influenced by the Surviving Sepsis
Campaign, as shown by the rate of early centralcatheter placement of 57% in the usual-care
group, a procedure that has been associated with
a 10% reduction in mortality.3 Even the delayed
introduction of monitoring of central venous
pressure and central venous oxygen saturation
after the 6-hour avoidance period can still give
rise to improved outcomes.4 Moreover, the high
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Table 1. Differences in Mortality and Key Clinical Values in the EGDT Study and the ProCESS Study.*
Variable

EGDT Study

ProCESS Study
Protocol-Based
Standard-Therapy Usual-Care
Group
Group

EGDT
Group

Control
Group

EGDT
Group

Predicted mortality on the basis of APACHE II
score (%)

40.3

36.9

38.2

37.5

37.9

Actual mortality (%)

30.5

46.5

21.0

18.2

18.9

At 0 hr

7.7

6.9

4.8

5.0

4.8

At 6 hr

4.3

4.9

NR

NR

NR

48.6

49.2

71.0

NA

NA

Lactate (mmol/liter)

Central venous oxygen saturation (%)
At 0 hr
At 6 hr
Central-catheter rate at 6 hr (%)

77.3

66.0

100

100

NR

NA

NA

93.6

56.5

57.9

* APACHE denotes Acute Physiology and Chronic Health Evaluation, NA not applicable, and NR not reported.

likelihood that the usual-care group received preexisting protocol-driven care, as outlined in the
Surviving Sepsis Campaign, could explain the
low mortality and small between-group differences (Table 1). Does it make sense to change a
historically successful protocol that has improved patient outcomes? The recent continued
endorsement of EGDT by the Surviving Sepsis
Campaign supports the status quo.5
Angel Coz Yataco, M.D.
University of Kentucky
Lexington, KY

angel.coz@uky.edu
No potential conflict of interest relevant to this letter was reported.
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To the Editor: Although it is indeed good news
that advances in the field have decreased shortn engl j med 371;4

term sepsis-related mortality over time since the
original report of EGDT,1,2 and that this lower
mortality may have influenced the ProCESS trial
results to some extent, it is important to recognize that only half the patients in the ProCESS
population were able to be discharged home
from the hospital, and the 1-year mortality appears to be nearly double the short-term mortality. Other recent studies have found similar discordance. As highlighted in the Journal,3 chronic
critical illness (i.e., critically illness in patients
who neither die in the acute phase nor recover) is
an emerging public health problem that is both
created and sustained by advances in critical care
medicine. How many patients in the ProCESS
study received the diagnosis of chronic critical
illness? And should the primary outcome in sepsis trials incorporate the occurrence of chronic
critical illness as a “poor” outcome?
Stephen Trzeciak, M.D., M.P.H.
Cooper University Hospital
Camden, NJ

trzeciak-stephen@cooperhealth.edu
No potential conflict of interest relevant to this letter was reported.
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To the Editor: The ProCESS trial represents a
little-understood paradigm shift. Twenty years
ago, when I began practicing emergency medicine, the administration of antibiotics without an
identified source of infection violated accepted
practice. We can quibble over monitoring of central venous pressure and lactate clearance. The
critical change, though, is that in this “new era,”
as described in the editorial accompanying the
article on the ProCESS trial,1 we are urged to
treat sepsis quickly on clinical evidence rather
than on delayed bacteriologic evidence.
Antonio J. Dajer, M.D.
New York Presbyterian–Lower Manhattan Hospital
New York, NY

tonydajer@aol.com
No potential conflict of interest relevant to this letter was reported.
1. Lilly CM. The ProCESS trial — a new era of sepsis manage-

ment. N Engl J Med 2014;370:1750-1.
DOI: 10.1056/NEJMc1406745

The authors reply: We agree with Priebe that
saline can cause hyperchloremia and acidosis. In
our study, we did not evaluate different fluid formulations. Saline comprised 93% of intravenous
fluids (range, 92 to 96% in the three study
groups) during the first 6 hours and 83% (range,
80 to 86%) from 6 hours to 72 hours, which we
consider within the scope of usual U.S. practice.1
We also agree with Dajer regarding the importance of the early use of antibiotics in patients
who appear to be sick and infected, such as patients enrolled in our study, although use of these
drugs in less sick patients may enhance antibiotic resistance.
Modern studies typically report outcomes
better than those predicted by the APACHE II
score, presumably because of the many advances
in care since the original APACHE II calibration
30 years ago.2 Coz Yataco notes that our cohort
had some features that suggested a lower severity
of illness than that in the study by Rivers et al.3
However, in our reported subgroup analyses, the
sickest third of patients on the basis of lactate
levels or APACHE II scores, who were sicker than
patients in the cohort study by Rivers et al.,
showed no benefit from EGDT. Thus, we do not
believe that differences in severity of illness explain
the differences in results between the two trials.
We disagree that central-catheter use in 57%
of patients in the control group is evidence that
sites all followed the EGDT-based resuscitation
386
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guidelines of the Surviving Sepsis Campaign.
Central-catheter use is extremely common, especially for patients admitted to the intensive care
unit. Furthermore, as we reported, only 3.5% and
4.0% of patients in the two control groups underwent monitoring of central venous oxygen saturation,1 a prerequisite for EGDT. Coz Yataco
suggests that the resuscitation bundle that is
recommended by the Surviving Sepsis Campaign
should remain intact because observational studies report good outcomes. We contend that clinical guidelines should be modified as robust data
emerge from randomized trials, and the Surviving Sepsis Campaign bundles have undergone
numerous changes in the past on the basis of
just such a process.4
We agree with Trzeciak that enthusiasm for
the decline in hospital mortality from sepsis must
be tempered by concern that many patients who
are discharged may die in the following months,
as we reported, or suffer protracted sequelae.
That said, in our study, only 45 of 1341 patients
(3.4%) were still undergoing mechanical ventilation at the time of discharge. We agree that assessing outcomes beyond short-term mortality
are key considerations for future sepsis trials.
Derek C. Angus, M.D., M.P.H.
Donald M. Yealy, M.D.
John A. Kellum, M.D.
University of Pittsburgh
Pittsburgh, PA

angusdc@upmc.edu
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The editorialist replies: Dajer astutely points
out that the one key element that the ProCESS
trial procedures shared with those in the preceding EGDT trial1 was that antimicrobials were administered within the first 2 hours after sepsis
was identified in circulatory failure. The practice
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Case 9-2014: A Woman with Increasing Dyspnea
To the Editor: Saukkonen et al. (March 20 issue)1 describe a 34-year-old woman with severe
pulmonary hypertension and Raynaud’s phenomenon due to mixed connective-tissue disease.
However, the authors never identified the cause
of severe systemic hypertension (which is not
typically seen in mixed connective-tissue disease)
in this patient. Particularly in light of her autoimmune disease, I wonder whether she was tested for the antiphospholipid syndrome. In one of
his early descriptions of this syndrome in 1984,
Hughes reported labile hypertension, often with
associated livedo reticularis, Raynaud’s phenomenon, or both.2 Indeed, since then, hypertension
— often severe — has been observed in as many
as 40 to 50% of patients with primary antiphospholipid syndrome. Hypertension in this syndrome
is most often renovascular in origin, including
not only thrombosis or focal arterial stenosis of
the renal artery, but also intrarenal thrombotic
microangiopathy (antiphospholipid syndrome nephropathy), and severe hypertension may be the
initial manifestation of the antiphospholipid
syndrome in these patients.3 Hypertension in this
syndrome may also occur as a result of an associated autonomic disorder (e.g., hyperadrenergic
postural tachycardia syndrome), and these patients also often have livedo reticularis, Raynaud’s
phenomenon, or both.4

n engl j med 371;4
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To the Editor: We would like to raise two issues
with regard to the Case Record by Saukkonen
et al. First, pulmonary veno-occlusive disease
should be considered in the differential diagnosis of pulmonary arterial hypertension associated with connective-tissue diseases. Pulmonary
arterial hypertension and pulmonary veno-occlusive disease share predisposing conditions and
clinical and hemodynamic features. The exclusion
of pulmonary veno-occlusive disease is crucial,
since patients with pulmonary veno-occlusive
disease, besides having a worse prognosis, may
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